OncoCyte Corporation — Form 10-Q Summary
Entity note: The supplied filing is OncoCyte Corporation’s Form 10-Q, not a filing identified as Insight Molecular Diagnostics Inc. It covers the quarter and nine months ended September 30, 2020; amounts below are in U.S. dollars unless noted.
Business context and reporting period
OncoCyte develops and commercializes cancer molecular diagnostic tests. Its DetermaRx lung-cancer test launched in early 2020; the company acquired Insight Genetics on January 31, 2020, adding pharma-services capabilities and DetermaIO, a test still under development for clinical use. OncoCyte also holds a 25% equity-method interest in Razor Genomics, which developed and licensed DetermaRx.
Financial performance and position
- Revenue: Q3 2020 revenue was $555,000; nine-month revenue was $713,000. The company had no revenue in the comparable 2019 periods. Q3 revenue mix was 37% DetermaRx and 63% pharma services; nine-month mix was 31% and 69%, respectively.
- Profit and margins: Q3 net loss was $6.8 million ($0.10 per share), versus $5.2 million ($0.10 per share) in Q3 2019. Nine-month net loss was $23.6 million ($0.36 per share), versus $14.5 million ($0.29 per share) in 2019. Cost of revenue exceeded revenue by $46,000 in Q3 and $426,000 for the nine months. The reported Q3 operating loss was $6.2 million; it includes a $3.0 million noncash gain from remeasuring acquisition-related contingent consideration.
- Expenses: Q3 research and development was $2.6 million, general and administrative $5.0 million, and sales and marketing $1.6 million. For the nine months, the respective amounts were $8.0 million, $13.4 million, and $4.6 million. Q3 and nine-month cost of revenue was $601,000 and $1.1 million.
- Cash flow: Nine-month operating cash use was $19.8 million and investing cash use was $11.3 million; financing provided $19.3 million, mainly from $18.3 million of share-sale proceeds and a $1.1 million PPP loan. Cash, cash equivalents and restricted cash totaled $12.0 million at September 30, including $10.3 million of unrestricted cash and $1.7 million of restricted cash.
- Liquidity and debt: Current assets were $12.0 million and current liabilities $8.9 million. Loans payable totaled approximately $4.1 million, excluding lease liabilities. Operating and financing lease liabilities totaled approximately $4.3 million. Total liabilities were $23.1 million; shareholders’ equity was $34.6 million.
Material changes versus the prior comparable period
- Revenue began in 2020 following DetermaRx’s launch and the Insight acquisition. Comparisons with 2019 are affected by the absence of prior-period revenue and by Insight being consolidated only from January 31, 2020.
- Nine-month net loss increased by $9.2 million. Research and development, general and administrative, and sales and marketing expenses rose as the company built its testing, administrative, and commercial operations.
- The Insight acquisition added $14.7 million of acquired DetermaIO in-process research and development, $9.2 million of goodwill, and an $8.2 million contingent-consideration liability at September 30. The liability declined $3.0 million from its acquisition-date fair value, primarily due to revised timing estimates for possible payments.
- Common shares outstanding increased to 67.3 million from 57.0 million at year-end 2019, reflecting equity issuance, including shares issued for Insight and shares sold for cash.
Outlook, management commentary and risks
- CMS issued a final DetermaRx pricing decision in September 2020. OncoCyte began recognizing revenue when tests are performed for Medicare patients; other-payer DetermaRx revenue generally remained recognized on a cash basis absent sufficient collection history or reimbursement agreements.
- Management stated that cash, marketable securities and access to its $25 million at-the-market equity program were expected to fund current operations for at least 12 months from the financial statements’ issuance date. The company nevertheless expects continued operating losses and says it will need additional capital until revenue can cover expenses. No specific revenue or earnings guidance was provided.
- COVID-19 could delay lung-cancer surgeries and clinical trials, constrain physician and customer outreach, disrupt suppliers or operations, and make financing more difficult. The company said it could not reliably quantify the pandemic’s effect on revenue or results.
- In June, management discontinued further significant DetermaDx development following clinical-validation results and redirected focus to DetermaRx and DetermaIO. Certain machinery and related assets were impaired; the filing reports a $422,000 impairment charge for the nine months.
- A September partial reduction in force and salary-reduction agreements resulted in approximately $1.3 million of accrued severance at quarter-end, including $0.7 million of accelerated stock-based compensation. OncoCyte reported no material litigation and said it was in compliance with its bank loan agreement as of the filing date.
Important facts for investors to verify
- Confirm the issuer identity: the filing is for OncoCyte Corporation, despite the request metadata naming Insight Molecular Diagnostics Inc.
- Track DetermaRx test volumes, realized collections, Medicare reimbursement and progress toward coverage by other payers; reported revenue remains small and payer/customer concentrations are significant.
- Assess cash burn, use and availability of the ATM facility, potential dilution, debt repayment obligations, and whether management’s stated liquidity runway remains supportable.
- Review DetermaIO development and commercialization milestones, the valuation and potential impairment of acquired intangible assets and goodwill, and possible milestone or royalty payments to Insight sellers.
- Consider COVID-19 effects, the DetermaDx discontinuation, and the operational and financial consequences of the workforce reductions.